Financial Performance - For the full year 2025, the company reported revenue of $2.939 billion, representing a growth of 16.7% year-over-year, and non-GAAP earnings per share of $3.98, growing 30.8% [5][24] - In Q4 2025, revenue totaled $826.4 million, growing 25.7% compared to Q4 2024, with non-GAAP EPS at $1.28, a growth of 52.1% [6][25] - The base business revenue for Q4 was $726.7 million, growing 10.6% year-over-year, with a consolidated Adjusted EBITDA margin of 33.9% [6][25] Business Line Performance - The U.S. spine business grew 10% in Q4 compared to the prior year quarter, continuing a trend of above-market growth [7][28] - Enabling Technologies revenue reached $55.6 million in Q4, growing 18.5% year-over-year, driven by increased sales of EGPS systems [11][27] - The trauma business delivered approximately 27% growth in Q4, supported by the uptake of the legacy trauma line and new product launches [15][16] Market Performance - U.S. revenue in Q4 was $665.3 million, growing 27.5% year-over-year, while international revenue was $161.1 million, growing 19% [27][28] - The international spine business faced challenges earlier in the year but showed incremental improvement, culminating in a record sales quarter in Q4 2025 [29][28] - Growth in international markets was led by enabling technologies and the spine business, particularly in the UK, Australia, Germany, Brazil, Mexico, and Poland [28] Company Strategy and Industry Competition - The company aims to penetrate and launch new programs while fostering utilization and service excellence across its install base, with a focus on innovation in product development [15][18] - The integration of Nevro is expected to enhance the company's portfolio, allowing entry into adjacent markets while driving differentiation in legacy businesses [18][17] - The company remains competitive in the evolving market landscape, emphasizing the unique capabilities of its ExcelsiusGPS platform [12][14] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of U.S. spine growth, citing product launches and an expanded sales force as key drivers [70] - The company anticipates continued margin expansion, with a target of achieving a gross profit margin in the range of 69%-70% for 2026 [32][43] - Management acknowledged the challenges faced in international markets but remains optimistic about returning to double-digit growth rates as the year progresses [81][80] Other Important Information - The company repurchased approximately 4.3 million shares during 2025, with a new share repurchase program of $500 million announced [38][39] - Full-year 2025 SG&A expenses were $1.178 billion, or 40% of sales, with expectations for 2026 to be in the range of 38%-39% [36][43] - The company achieved $200 million in synergies from the NuVasive acquisition, exceeding initial targets [41][42] Q&A Session Summary Question: Can you bridge the growth expectations for the base business from 2025 to 2026? - Management noted that 2025 was a tale of two halves, with significant growth in the latter half driven by product launches and sales force expansion [49][50] Question: How did the company perform in terms of market share and the strength of the spine market? - Management believes the U.S. spine business is growing above market, with evidence from consistent growth rates [56][57] Question: What contributed to the recovery in enabling technology performance? - Management indicated that the fourth quarter saw a closure of delayed pipeline deals, contributing to the improved performance [62][63] Question: How sustainable is the U.S. spine growth, especially with new competition? - Management expressed confidence in the durability of U.S. spine growth, emphasizing ongoing product launches and competitive strategies [70][71] Question: What are the challenges and growth prospects for the international business? - Management highlighted the potential for 12%-15% growth in international markets, focusing on deeper penetration rather than expansion into new countries [81][80]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenue of $213 million, representing a 20% year-over-year growth and a 21% growth in surgical revenue [3][6] - For the full year 2025, total revenue reached $764 million, a $153 million increase year-over-year, equating to a 25% total revenue growth [4][16] - Adjusted EBITDA for Q4 was $33 million, reflecting a 61% year-over-year increase, with a margin of 16% [15][24] - The full year Adjusted EBITDA was $93 million, approximately 12% of sales, marking a significant improvement of $63 million year-over-year [17][24] Business Line Data and Key Metrics Changes - Surgical revenue in Q4 was $190 million, up 21% year-over-year, while EOS revenue was $23 million, up 14% year-over-year [6][8] - For the full year, surgical revenue totaled $687 million, a 26% increase compared to 2024, driven by a 22% growth in procedural volume [16][17] - EOS revenue for the full year was $77 million, reflecting a 15% year-over-year growth [16] Market Data and Key Metrics Changes - U.S. revenue per case increased by 1.4%, with lateral and cervical procedures both up 6% [7] - Same-store sales in the U.S. grew 20% year-over-year, indicating strong growth in established territories [8] Company Strategy and Development Direction - The company is focused on creating clinical distinction through proceduralization, particularly in lateral surgery, which is seen as a growth engine [26][29] - ATEC is expanding its sales force and enhancing its product offerings, including the introduction of advanced technologies like the Valence platform for intraoperative navigation [27][28] - The company aims to leverage its unique ecosystem to address complex pathologies in spine surgery, enhancing surgeon confidence and patient outcomes [30][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of top-line growth, driven by increasing surgeon adoption and procedural volume [9][19] - The outlook for 2026 anticipates revenue growth of 17% to approximately $890 million, with Adjusted EBITDA guidance increased to $134 million [19][24] - The company is positioned for long-term profitable growth, focusing on expanding its infrastructure and integrating data into surgical experiences [38][39] Other Important Information - The company ended Q4 with $161 million in cash and had access to an additional $60 million in undrawn credit, totaling $221 million in available cash [18] - Free cash flow for Q4 was $8 million, marking the first full year of positive free cash flow for the company [18][19] Q&A Session Summary Question: Concerns about share trading post-earnings - Management confirmed that Q4 results were in line with expectations, with EBITDA exceeding consensus by 10% and 2026 revenue guidance reaffirmed [44][45] Question: Cadence for 2026 revenue and EBITDA - Management indicated that Q1 revenue is expected to follow a similar seasonal pattern as 2025, with Q1 contributing about 22.1% of sales [47][48] Question: Attracting sales talent - Management stated that the hiring process is going well, with strong demand for the company's portfolio from both surgeons and sales personnel [53]

Company Overview - Alphatec Holdings specializes in advanced spinal surgery systems, including neural monitoring, fixation, and implant technologies, as well as biologics and imaging products [7][8] - The company generates revenue primarily through the direct sale and distribution of proprietary medical devices and surgical solutions for spinal disorder treatments, targeting hospitals, surgeons, and healthcare providers in the U.S. [7][8] - For the trailing twelve months (TTM), Alphatec reported revenue of $728.02 million and a net income loss of $154.96 million [4] Recent Insider Activity - Scott Lish, the Chief Operating Officer, sold 19,900 shares for approximately $390,836 on December 16, 2025, which represents a 3.01% decrease in his direct holdings, leaving him with 641,432 shares post-sale [1][2][6] - The sale aligns with Lish's median trade size and reflects a consistent selling pattern amid strong share price appreciation [6] Market Performance - Alphatec's shares experienced a 127.08% price change over the past year, with a notable total return of 108.7% [4][6] - The stock reached a 52-week high of $22.66 on November 26, significantly up from a low of $8.81 in April [10] - The company's third-quarter revenue of $197 million marked a 30% year-over-year increase, with a gross margin of 70% [11] Investment Considerations - Despite the insider selling, the transaction does not raise concerns as Lish retains a substantial number of shares [9] - The current price-to-sales ratio of over four indicates a favorable market environment for selling shares, especially given the company's trajectory towards profitability [10][11] - Investors are advised to consider waiting for a potential drop in share price before making new investments in Alphatec [12]